Patent application number | Description | Published |
20100092485 | Genetic Markers for Predicting Responsiveness to Combination Therapy - The invention provides compositions and methods for determining the likelihood of successful treatment with an effective amount of an anti-VEGF antibody or equivalent thereof, in combination with anti-EGFR antibody or equivalent thereof, and, in some aspects in combination with a topoisomerase inhibitor. The methods comprise determining the identity of a gene of interest in a patient sample and correlating the patient's genotype with the predictive response. Patients identified as responsive are then treated with the appropriate therapy. | 04-15-2010 |
20100099720 | Gene Polymorphisms as Sex-Specific Predictors in Cancer Therapy - The invention provides compositions and methods for determining the likelihood of gender-specific successful treatment with 5-FU/oxaliplatin or an equivalent of each thereof. The methods comprise determining the genomic polymorphism present in a predetermined region of a gene of interest and correlating the polymorphism to the predictive response. Patients identified as responsive are then treated with the appropriate therapy. | 04-22-2010 |
20100104583 | Gene Polymorphisms in VEGF and VEGF Receptor 2 as Markers for Cancer Therapy - The invention provides compositions and methods for determining the likelihood of successful treatment with anti-angiogenic antibodies or equivalent thereof, in combination with a pyrimidine based antimetabolite and a platinum-based alkylating agent based therapy. The methods comprise determining the genomic polymorphism present in a predetermined region of a gene of interest and correlating the polymorphism to the predictive response. Patients identified as responsive are then treated with the appropriate therapy. | 04-29-2010 |
20100113459 | Gene Polymorphisms as Predictors of Tumor Progression and Their Use in Cancer Therapy - The invention provides compositions and methods for determining the likelihood of successful treatment with a pyrimidine based antimetabolite chemotherapy drug and a platinum based chemotherapy drug, such as 5-FU/oxaliplatin. The methods comprise determining the genomic polymorphism present in a predetermined region of a gene of interest and correlating the polymorphism to the predictive response. Patients identified as responsive are then treated with the appropriate therapy. | 05-06-2010 |
20100152202 | Tissue Factor Promoter Polymorphisms - The invention provides compositions and methods for determining the likelihood of successful treatment with a pyrimidine based antimetabolite chemotherapy drug such as 5-fluorouracil or in combination with a platinum based chemotherapy drug, such as 5-fluorouracil/oxaliplatin. The methods comprise determining the genomic polymorphism present in a predetermined region of a gene of interest and correlating the polymorphism to the predictive response. Patients identified as responsive are then treated with the appropriate therapy. | 06-17-2010 |
20100172901 | Polymorphisms in the EGFR Pathway as Markers for Cancer Treatment - The invention provides compositions and methods for identifying patients for single agent anti-EGFR therapy. The methods comprise determining the genomic polymorphism present in a predetermined region of a gene of interest and correlating the polymorphism to the predictive response. Patients identified as responsive are then treated with the appropriate therapy. | 07-08-2010 |
20100173922 | Polymorphisms for Predicting Disease and Treatment Outcome - The invention provides compositions and methods for determining the increased risk for recurrence of certain cancers and the likelihood of successful treatment with one or both of chemotherapy and radiation therapy. The methods comprising determining the type of genomic polymorphism present in a predetermined region of the gene of interest isolated from the subject or patient. Also provided are nucleic acid probes and kits for determining a patient's cancer risk and treatment response. | 07-08-2010 |
20100183593 | Gene Polymorphisms Predictive for Dual TKI Therapy - The invention provides compositions and methods for determining the likelihood of successful treatment with dual therapy such as lapatinib. The methods comprise determining the genomic polymorphism or expression level of a gene present in a predetermined region of a gene of interest and correlating the polymorphism or expression level to the predictive response. Patients identified as likely responsive are then treated with the appropriate therapy. | 07-22-2010 |
20100184773 | Germline Polymorphisms in the Angiogenic Pathway Predict Tumor Recurrence in Cancer Therapy - The invention provides compositions and methods for determining the likelihood of successful treatment with pyrimidine based antimetabolites and platinum-based alkylating agents. The methods comprise determining the identity of one or more genomic polymorphism present in a predetermined region of a gene of interest and correlating the polymorphism to the predictive response and treatment options. Patients identified as responsive are then treated with the appropriate therapy. | 07-22-2010 |
20100216826 | Polymorphisms in Voltage-Gated Sodium Channel Alpha 1-Subunit as Markers for Therapy Selection - A method for determining whether a patient in need thereof will respond to chemotherapy by screening a suitable sample isolated from the patient for a pre-selected polymorphism present in the VGSC gene. | 08-26-2010 |
20100233719 | Genetic Markers for Predicting Disease and Treatment Outcome - The present invention provides for a method for identifying patients that are suitably treated by a therapy, such as a therapy involving administration of a fluoropyrimidine drug and/or a platinum drug. The method includes determining the expression level of at least one gene selected from a phospholipase 2 (PLA2) gene, a thymidine phosphorylase (TP) gene, and a glutathione S-transferase P1 (GSTP-1) gene in suitable sample isolated from the patient. Overexpression of the gene or genes identifies the patient as not being suitable for the therapy. | 09-16-2010 |
20100286179 | EGFR POLYMORPHISMS PREDICT GENDER-RELATED TREATMENT - The invention provides compositions and methods for identifying a gender-specific cancer patient suitable for treatment with various treatment regimens available to cancer patients. After determining if a patient is suitable for therapy, the invention also provides methods for treating these patients. | 11-11-2010 |
20110020333 | Angiogenesis Pathway Gene Polymorphisms for Therapy Selection - A method for determining whether a patient in need thereof will respond to anti-VEGF antibody based chemotherapy by screening a suitable cell or tissue sample isolated from the patient for at least one genomic polymorphism or genotype selected from (i) IL-8(−251); (ii) VEGF(936); or (iii) AM (3′ CA repeats), wherein the patient is suitably treated if the corresponding genotype is (i) (T/T) for IL-8(−251); (ii) (T/T or C/T) for VEGF(936); or (iii) at least one AM allele having 14 or more 3′ CA repeats. | 01-27-2011 |
20110105529 | ERCC-1 Gene Expression Predicts Chemotherapy Outcome - The invention provides compositions and methods for determining the likelihood of successful treatment with a first line FOLFOX chemotherapy regimen or in further combination with PTK/ZK. The methods comprise determining the gene expression levels of a gene of interest and correlating the high or low expression to the predictive response. Patients identified as responsive are then treated with the appropriate therapy. | 05-05-2011 |
20110160216 | Thymidylate Synthase Haplotype is Associated with Tumor Recurrence in Stage II and Stage III Colon Cancer Patients - The invention provides compositions and methods for determining the likelihood of tumor recurrence following treatment with 5-FU based adjuvant therapy for Stage II or Stage III colon cancer patients. After determining if a patient is less likely to experience tumor recurrence once treated, the invention also provides methods for treating these patients. | 06-30-2011 |
20110178110 | Genotype and Expression Analysis for Use in Predicting Outcome and Therapy Selection - The invention provides compositions and methods for determining the likelihood of successful treatment with a various treatment regimens available to gastrointestinal cancer patients. After determining if a patient is likely to be successfully treated, the invention also provides methods for treating these patients. | 07-21-2011 |
20120020984 | Genetic Markers for Predicting Responsiveness to Combination Therapy - The invention provides compositions and methods for determining the likelihood of successful treatment with an effective amount of an anti-VEGF antibody or equivalent thereof, in combination with anti-EGFR antibody or equivalent thereof, and, in some aspects in combination with a topoisomerase inhibitor. The methods comprise determining the identity of a gene of interest in a patient sample and correlating the patient's genotype with the predictive response. Patients identified as responsive are then treated with the appropriate therapy. | 01-26-2012 |
20120077685 | INTRATUMORAL GENE EXPRESSION LEVELS OF TP AND VEGF ARE ASSOCIATED WITH CLINICAL OUTCOMES IN RECTAL CANCER PATIENTS TREATED WITH 5-FLUOROURACIL AND PELVIC RADIATION - The disclosure provides compositions and methods for identifying a cancer patient suitable or not suitable for a therapy that includes administration of a pyrimidine antimetabolite such as 5-fluorouracil. After determining if a patient is likely to be successfully treated, the disclosure also provides methods for treating these patients. | 03-29-2012 |
20120094844 | GENETIC VARIANTS IN IL-6, P53, MMP-9 AND CXCR PREDICT CLINICAL OUTCOME IN PATIENTS WITH CANCER - The invention provides compositions and methods for determining the likelihood of response or survival of cancer patients treated with anti-VEGF therapy. After determining if a patient is likely to be successfully treated, the invention also provides methods for treating the patients. | 04-19-2012 |
20120100134 | GENETIC VARIANTS IN ANGIOGENESIS PATHWAY ASSOCIATED WITH CLINICAL OUTCOME - The invention provides methods for determining the clinical outcomes for treatment with various treatment regimens available to cancer patients based on genotypes of the patients for genetic polymorphism markers. The invention also provides kits for making the determination. | 04-26-2012 |
20120100135 | GENETIC POLYMORPHISMS ASSOCIATED WITH CLINICAL OUTCOMES OF TOPOISOMERASE INHIBITOR THERAPY FOR CANCER - The invention provides compositions and methods for determining the likelihood of response or survival of cancer patients treated with topoisomerase inhibitor therapy or anti-EGFR and topoisomerase inhibitor therapy combination therapy. After determining if a patient is likely to be successfully treated, the invention also provides methods for treating the patients. | 04-26-2012 |
20120100997 | CD133 POLYMORPHISMS AND EXPRESSION PREDICT CLINICAL OUTCOME IN PATIENTS WITH CANCER - The invention provides compositions and methods for aiding in the determination of or determining whether or not a cancer patient is likely to be responsive to a therapy comprising the administration of an anti-VEGF therapy. After determining if a patient is likely to be successfully treated, the invention also provides methods for treating the patients. | 04-26-2012 |
20120107308 | GENE EXPRESSION LEVELS OF EGFR, VEGFR2, AND ERCC1 ASSOCIATED WITH CLINICAL OUTCOMES OF CHEMOTHERAPY - The invention provides compositions and methods for identifying a cancer patient suitable for anti-VEGF therapy. After determining if a patient is likely to be successfully treated, the invention also provides methods for treating the patients. | 05-03-2012 |
20120107309 | POLYMORPHISM IN K-RAS 3' UNTRANSLATED REGION ASSOCIATED WITH CLINICAL OUTCOMES OF CANCER TREATMENTS INDEPENDENT OF K-RAS MUTATION STATUS - The invention provides compositions and methods for determining the likelihood of response or survival of cancer patients treated with anti-EGFR therapy, topoisomerase inhibitor therapy or anti-EGFR therapy/topoisomerase inhibitor therapy combination therapy. After determining if a patient is likely to be successfully treated, the invention also provides methods for treating the patients. | 05-03-2012 |
20120108441 | POLYMORPHISMS IN ANGIOGENESIS PATHWAY GENES ASSOCIATED WITH TUMOR RECURRENCE IN SURGERY TREATED CANCER PATIENTS - This invention provides compositions and methods for determining the likely tumor recurrence of cancer patients after surgical resection. Said methods are based on determining the patient's genotype for the polymorphisms PAR-1-506 ins/del C and/or EGF+61A>G. | 05-03-2012 |
20120108445 | VEGF AND VEGFR1 GENE EXPRESSION USEFUL FOR CANCER PROGNOSIS - The invention provides compositions and methods for determining the likelihood of tumor recurrence of adjuvant cancer patients following surgical resection. | 05-03-2012 |
20120122946 | POLYMORPHISMS FOR PREDICTING DISEASE AND TREATMENT OUTCOME - The invention provides compositions and methods for determining the increased risk for recurrence of certain cancers and the likelihood of successful treatment with one or both of chemotherapy and radiation therapy. The methods comprising determining the type of genomic polymorphism present in a predetermined region of the gene of interest isolated from the subject or patient. Also provided are nucleic acid probes and kits for determining a patient's cancer risk and treatment response. | 05-17-2012 |
20130196955 | POLYMORPHISMS FOR PREDICTING DISEASE AND TREATMENT OUTCOME - The invention provides compositions and methods for determining the increased risk for recurrence of certain cancers and the likelihood of successful treatment with one or both of chemotherapy and radiation therapy. The methods comprising determining the type of genomic polymorphism present in a predetermined region of the gene of interest isolated from the subject or patient. Also provided are nucleic acid probes and kits for determining a patient's cancer risk and treatment response. | 08-01-2013 |